FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Vashington,	D.C.	20549	
-------------	------	-------	--

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden 0.5 hours per response:

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* <u>Calais Philippe</u>					2. Issuer Name and Ticker or Trading Symbol Transcode Therapeutics, Inc. [RNAZ]						(Ch	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
(Last)	(F	irst)	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 05/19/2023							(give title		specify	
C/O TRANSCODE THERAPEUTICS, INC. 6 LIBERTY SQUARE, #2382				4. If <i>i</i>	4. If Amendment, Date of Original Filed (Month/Day/Year)					Line	Individual or Joint/Group Filing (Check Applicable le) X Form filed by One Reporting Person					
(Street)	N M	A	02109			_								iled by More	than One Rep	I
(City)	(S	tate)	(Zip)		_	Chec	k this box	to inc	Transa dicate that a trade defense cond	nsaction was	made pursua	ant to a con	tract, instructi on 10.	on or written	plan that is intend	led to
		Tab	le I - Nor	ı-Deriv	ative	Sec	curities	s Ac	quired, D	isposed	of, or Be	neficial	ly Owned	t		
1. Title of Security (Instr. 3) 2. Transar Date (Month/Date)				Execution Date		Code (Instr. 5)		red (A) or str. 3, 4 an	, 4 and Securities Beneficially Owned Follow		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership				
									Code	/ Amoun	t (A) c	Price	Reporte Transac (Instr. 3	tion(s)		(Instr. 4)
		Т							uired, Dis s, options				Owned			
Derivative Conversion Date		3. Transaction Date (Month/Day/Year)	Execution Date, T		4. Transaction of Octode (Instr. 8) Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		ive ies ed	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (right to buy)	\$0.2834	05/19/2023			A		45,000		(1)	05/18/2033	Common Stock	45,000	\$0.00	45,000	D	

Explanation of Responses:

1. The shares subject to this option shall vest and become exercisable in full on December 31, 2023, subject to the Reporting Person's continued service at such time.

/s/ Thomas A. Fitzgerald, as Attorney-in-Fact ** Signature of Reporting Person

05/19/2023

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.